1975 - 1995 Revised anti-cancer serological response: Biological significance and clinical implications

S. Canevari, S. M. Pupa, S. Ménard

Research output: Contribution to journalArticle

Abstract

In the 1970s a considerable amount of work was carried out in an attempt to identify an anti-tumor serological response in cancer patients. These analyses have not been very informative due to the complexity and heterogeneity of the response. More recently, the availability of recombinant molecules, synthetic peptides and analytic and semi-quantitative assays has enabled a better dissection of humoral immunity. Antibodies against intracelluiar antigens (c-myb, c-myc, p53 and p21 ras) have been found in a significant, albeit varying, proportion of patients bearing various tumors. Association with a poor prognosis is documented for anti-p53 antibodies in breast carcinoma patients. A number of cell surface antigens, including mucins, oncoproteins and carbohydrate antigens have been found to elicit a humoral immune response and, in some instances, circulating immune complexes were observed. A protective role for or, on the other hand, masking effects of such antibodies is still controversial. An indication that a serological response can be beneficial comes from vaccination studies. A significant association between the development of an anti-tumor antigen antibody response and prolonged survival was observed following vaccination of melanoma patients with GM2 or anti-idiotypic antibodies which molecularly mimic tumor-associated antigens. It is to be hoped that in the near future the numerous ongoing immunization trials and prognostic studies demonstrate whether antibody response can exert a protective role in vivo.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalAnnals of Oncology
Volume7
Issue number3
Publication statusPublished - Mar 1996

Fingerprint

Neoplasm Antigens
Humoral Immunity
Antibody Formation
Anti-Idiotypic Antibodies
Neoplasms
Vaccination
Proto-Oncogene Proteins p21(ras)
Neoplasm Antibodies
Antigens
Antibodies
Oncogene Proteins
Mucins
Surface Antigens
Antigen-Antibody Complex
Dissection
Melanoma
Immunization
Carbohydrates
Breast Neoplasms
Peptides

Keywords

  • Prognosis
  • Serological response
  • TAA
  • Therapy
  • Vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

1975 - 1995 Revised anti-cancer serological response : Biological significance and clinical implications. / Canevari, S.; Pupa, S. M.; Ménard, S.

In: Annals of Oncology, Vol. 7, No. 3, 03.1996, p. 227-232.

Research output: Contribution to journalArticle

@article{050c4c24c001489e8539b0684e74001b,
title = "1975 - 1995 Revised anti-cancer serological response: Biological significance and clinical implications",
abstract = "In the 1970s a considerable amount of work was carried out in an attempt to identify an anti-tumor serological response in cancer patients. These analyses have not been very informative due to the complexity and heterogeneity of the response. More recently, the availability of recombinant molecules, synthetic peptides and analytic and semi-quantitative assays has enabled a better dissection of humoral immunity. Antibodies against intracelluiar antigens (c-myb, c-myc, p53 and p21 ras) have been found in a significant, albeit varying, proportion of patients bearing various tumors. Association with a poor prognosis is documented for anti-p53 antibodies in breast carcinoma patients. A number of cell surface antigens, including mucins, oncoproteins and carbohydrate antigens have been found to elicit a humoral immune response and, in some instances, circulating immune complexes were observed. A protective role for or, on the other hand, masking effects of such antibodies is still controversial. An indication that a serological response can be beneficial comes from vaccination studies. A significant association between the development of an anti-tumor antigen antibody response and prolonged survival was observed following vaccination of melanoma patients with GM2 or anti-idiotypic antibodies which molecularly mimic tumor-associated antigens. It is to be hoped that in the near future the numerous ongoing immunization trials and prognostic studies demonstrate whether antibody response can exert a protective role in vivo.",
keywords = "Prognosis, Serological response, TAA, Therapy, Vaccination",
author = "S. Canevari and Pupa, {S. M.} and S. M{\'e}nard",
year = "1996",
month = "3",
language = "English",
volume = "7",
pages = "227--232",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - 1975 - 1995 Revised anti-cancer serological response

T2 - Biological significance and clinical implications

AU - Canevari, S.

AU - Pupa, S. M.

AU - Ménard, S.

PY - 1996/3

Y1 - 1996/3

N2 - In the 1970s a considerable amount of work was carried out in an attempt to identify an anti-tumor serological response in cancer patients. These analyses have not been very informative due to the complexity and heterogeneity of the response. More recently, the availability of recombinant molecules, synthetic peptides and analytic and semi-quantitative assays has enabled a better dissection of humoral immunity. Antibodies against intracelluiar antigens (c-myb, c-myc, p53 and p21 ras) have been found in a significant, albeit varying, proportion of patients bearing various tumors. Association with a poor prognosis is documented for anti-p53 antibodies in breast carcinoma patients. A number of cell surface antigens, including mucins, oncoproteins and carbohydrate antigens have been found to elicit a humoral immune response and, in some instances, circulating immune complexes were observed. A protective role for or, on the other hand, masking effects of such antibodies is still controversial. An indication that a serological response can be beneficial comes from vaccination studies. A significant association between the development of an anti-tumor antigen antibody response and prolonged survival was observed following vaccination of melanoma patients with GM2 or anti-idiotypic antibodies which molecularly mimic tumor-associated antigens. It is to be hoped that in the near future the numerous ongoing immunization trials and prognostic studies demonstrate whether antibody response can exert a protective role in vivo.

AB - In the 1970s a considerable amount of work was carried out in an attempt to identify an anti-tumor serological response in cancer patients. These analyses have not been very informative due to the complexity and heterogeneity of the response. More recently, the availability of recombinant molecules, synthetic peptides and analytic and semi-quantitative assays has enabled a better dissection of humoral immunity. Antibodies against intracelluiar antigens (c-myb, c-myc, p53 and p21 ras) have been found in a significant, albeit varying, proportion of patients bearing various tumors. Association with a poor prognosis is documented for anti-p53 antibodies in breast carcinoma patients. A number of cell surface antigens, including mucins, oncoproteins and carbohydrate antigens have been found to elicit a humoral immune response and, in some instances, circulating immune complexes were observed. A protective role for or, on the other hand, masking effects of such antibodies is still controversial. An indication that a serological response can be beneficial comes from vaccination studies. A significant association between the development of an anti-tumor antigen antibody response and prolonged survival was observed following vaccination of melanoma patients with GM2 or anti-idiotypic antibodies which molecularly mimic tumor-associated antigens. It is to be hoped that in the near future the numerous ongoing immunization trials and prognostic studies demonstrate whether antibody response can exert a protective role in vivo.

KW - Prognosis

KW - Serological response

KW - TAA

KW - Therapy

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0029921936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029921936&partnerID=8YFLogxK

M3 - Article

C2 - 8740784

AN - SCOPUS:0029921936

VL - 7

SP - 227

EP - 232

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -